Modality
ASO
MOA
BETi
Target
GPRC5D
Pathway
Cell Cycle
MSMigraineMCL
Development Pipeline
Preclinical
~Apr 2013
→ ~Jul 2014
Phase 1
~Oct 2014
→ ~Jan 2016
Phase 2
~Apr 2016
→ ~Jul 2017
Phase 3
Oct 2017
→ Jul 2031
Phase 3Current
NCT07595467
2,813 pts·MCL
2024-07→2026-03·Active
NCT08025136
1,641 pts·MS
2017-10→2031-07·Recruiting
NCT07706066
1,300 pts·Migraine
2021-10→2031-06·Completed
5,754 total pts3 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2026-03-283d agoPh3 Readout· MCL
2031-06-265.2y awayPh3 Readout· Migraine
2031-07-255.3y awayPh3 Readout· MS
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Recruit…
P3
Complet…
P3
Active
Catalysts
Ph3 Readout
2026-03-28 · 3d ago
MCL
Ph3 Readout
2031-06-26 · 5.2y away
Migraine
Ph3 Readout
2031-07-25 · 5.3y away
MS
RecruitingActiveCompleted|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07595467 | Phase 3 | MCL | Active | 2813 | EDSS |
| NCT08025136 | Phase 3 | MS | Recruiting | 1641 | SRI-4 |
| NCT07706066 | Phase 3 | Migraine | Completed | 1300 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D |